Juan Sanchez - Intra Cellular Insider

ITCI -- USA Stock  

USD 18.95  0.13  0.68%

Dr. Juan F. Sanchez, M.D., is Vice President Corporationrationrate Communications of IntraCellular Therapies, Inc. Previously, he was a healthcare research analyst at investment banking firm Ladenburg Thalmann Co. Inc., with a deep focus on companies specializing in central nervous system diseases from 2008 to 2014, most recently as a Managing Director. Prior to that time, he was a Vice President of healthcare and nanotechnology equity research at investment banking firm Punk, Ziegel, Co. Dr. Sanchez received his Master in International Affairs from Columbia University and his MBA from University of Los Andes in Bogota, Colombia. Dr. Sanchez practiced medicine for five years in his native country, Colombia, having received a medical degree from Pontifical Xavierian University, in Bogota.
Age: 43  President Since 2014      
646-440-9333  http://www.intracellulartherapies.com

Management Efficiency

The company has return on total asset (ROA) of (17.14) % which means that it has lost $17.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (27.39) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives


Joseph LaRosaRegeneron Pharmaceuticals
Caryn McDowellRevance Therapeutics
Kathryn SteinMacroGenics
Douglas McCorkleRegeneron Pharmaceuticals
Thomas SpitznagelMacroGenics
Ezio BonviniMacroGenics
Jeffrey SmithAlder Biopharmaceuticals
Christopher LeMastersMirati Therapeutics
Erin LancianiSage Therapeutics
Isan ChenMirati Therapeutics
Jon WiggintonMacroGenics
Sharon HallRevance Therapeutics
Debra ZackXencor
Marcy GrahamMirati Therapeutics
Christopher SilberSage Therapeutics
Amy SchacterleSage Therapeutics
George YancopoulosRegeneron Pharmaceuticals
Wayne SavilleXencor
Lauren SilvernailRevance Therapeutics
James BucherAlder Biopharmaceuticals
Peter PowchikRegeneron Pharmaceuticals

Entity Summary

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on NASDAQ. It employs 49 people.Intra Cellular Therapies (ITCI) is traded on NASDAQ in USA. It is located in 430 East 29th Street and employs 49 people.

Intra Cellular Thera Leadership Team

Lawrence Wennogle, Vice President of Drug Discovery
Christopher Alafi, Director
Michael Rawlins, Director
Robert Nostrand, Independent Director
Richard Lerner, Director
Robert Davis, Senior Vice President and Chief Scientific Officer
Allen Fienberg, Co-Founder and VP of Bus. Devel.
Michael Halstead, Sr. VP, General Counsel and Secretary
Sharon Mates, Co-Founder, Chairman, CEO and Pres
Andrew Satlin, Executive Vice President and Chief Medical Officer
Juan Sanchez, Vice President - Corporate Communications and Investor Relations
Rory Riggs, Independent Director
Joel Marcus, Director
Kimberly Vanover, VP of Clinical Devel.
Lawrence Hineline, Vice President and CFO

Stock Performance Indicators

Did you try this?

Run CEO Directory Now

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch CEO Directory

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.